Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of$ 0.42. This compares to loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.76%. A quarter ago, it was expected that this clinical-stage biotech company that develops stem cell treatments would post a loss of$ 0.47 per share when it actually produced a loss of $0.33, delivering a surprise of 2 ...